Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Falk Gastro Review Journal

    Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

    Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

    The latest issues

    Edition 4/2024

    read more

    Edition 3/2024

    read more

    Edition 2/2024

    read more

    Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

    All articles

    Liver and Bile

    Long-term outcome of autoimmune hepatitis: Consecutive patient cohort and data on the second 20 years

    Dig Liver Dis. 2023;55(11):1515–20

    Harrison L, Hoeroldt B, Dhaliwal H, Wadland E, Dube A, Gleeson D

    Go to article

    Liver and Bile

    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: A multicohort study

    Lancet. 2023;402(10406):988–96

    Serra-Burriel M, Juanola A, Serra-Burriel F, Thiele M, Graupera I, Pose E, Pera G, Grgurevic I, Caballeria L, Piano S, van Kleef L, Reichert M, Roulot D, Pericàs JM, Schattenberg JM, Tsochatztis EA, Guha IN, Garcia-Retortillo M, Hernández R, Hoyo J, Fuentes M, Expósito C, Martínez A, Such P, Madir A, Detlefsen S, Tonon M, Martini A, Ma AT, Pich J, Bonfill E, Juan M, Soria A, Carol M, Gratacós-Ginès J, Morillas RM, Toran P, Navarrete JM, Torrejón A, Fournier C, Llorca A, Arslanow A, de Koning HJ, Cucchietti F, Manns M, Newsome PN, Hernáez R, Allen A, Angeli P, de Knegt RJ, Karlsen TH, Galle P, Wong VWS, Fabrellas N, Castera L, Krag A, Lammert F, Kamath PS, Ginès P; LiverScreen Consortium Investigators

    Go to article

    Liver and Bile

    Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study

    J Hepatol. 2023;79(5):1085–95

    Roca-Fernandez A, Banerjee R, Thomaides-Brears H, Telford A, Sanyal A, Neubauer S, Nichols TE, Raman B, McCracken C, Petersen SE, Ntusi NA, Cuthbertson DJ, Lai M, Dennis A, Banerjee A

    Go to article

    Liver and Bile

    Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomized, open-label, international phase 3 study

    Lancet. 2023;402(10408):1133-1146

    Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group

    Go to article

    Liver and Bile

    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomized, open-label, multicenter, phase 3 trial

    Lancet. 2023;402(10415):1835–47

    Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators

    Go to article

    Liver and Bile

    Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial

    J Hepatol. 2023;79(5):1150–8

    Kuter DJ, Bonkovsky HL, Monroy S, Ross G, Guillén-Navarro E, Cappellini MD, Minder AE, Hother-Nielsen O, Ventura P, Jia G, Sweetser MT, Thapar M; ENVISION Investigators

    Go to article

    Liver and Bile

    Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating event

    Hepatology. 2023;78(4):1149–58

    Tonon M, Balcar L, Semmler G, Calvino V, Scheiner B, Incicco S, Barone A, Paternostro R, Gambino CG, Bauer DJM, Accetta A, Hartl L, Brocca A, Jachs M, Trauner M, Mandorfer M, Angeli P, Reiberger T, Piano S

    Go to article

    Liver and Bile

    Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient-reported outcomes: The Mi-Kristal trial

    Hepatology. 2023;78(4):1159–67

    Tapper EB, Ospina E, Salim N, Chen X, Nikirk S

    Go to article

    Liver and Bile

    Impact of continued alcohol use on liver-related outcomes of alcohol-associated cirrhosis: A retrospective study of 440 patients

    Eur J Gastroenterol Hepatol. 2024;36(1):89–96

    Kalambokis GN, Chouliara N, Tsiakas I, Filippas-Ntekuan S, Christaki M, Despotis G, Milionis H

    Go to article